Updated clinical-trial listings dated November 5, 2026, identify an expanded international network of research centers participating in the TEADCO study, which is investigating the experimental drug ODM-212 with established cancer treatments. The study includes a mesothelioma group combining ODM-212 with nivolumab and ipilimumab.
Registry-derived listings identify approximately two dozen study locations across seven countries, including five in the United States. These are locations for the overall study, not confirmed openings in the mesothelioma-specific group at every center. Patients should verify cohort availability directly with investigators.
The expansion concerns access to clinical research. No clinical efficacy results have been reported for this experimental combination in mesothelioma.
What is ODM-212?
ODM-212 is an investigational oral medicine designed to inhibit TEAD proteins involved in the Hippo signaling pathway, a system that helps regulate cell growth. Changes affecting this pathway occur in some mesothelioma tumors, and researchers are studying whether TEAD inhibition might interfere with tumor growth. ODM-212 is not an FDA-approved mesothelioma treatment.
What is the TEADCO study testing?
Orion Pharma's Phase I/II TEADCO study is evaluating ODM-212 in combination with existing cancer treatments. Its mesothelioma group combines ODM-212 with nivolumab and ipilimumab, immune-checkpoint inhibitors used together for certain patients with unresectable pleural mesothelioma.
Investigators are examining safety, tolerability, dosing, and preliminary antitumor activity. The study also includes separate groups involving pancreatic cancer and non-small cell lung cancer. Findings in those groups cannot be assumed to apply to mesothelioma.
Where are the U.S. study locations?
Updated trial-derived listings identify these five U.S. research locations:
- UC Irvine Health — Orange, California
- Valkyrie Clinical Trials — Los Angeles, California
- START Dallas–Fort Worth — Fort Worth, Texas
- NEXT Oncology — Irving, Texas
- NEXT Oncology Virginia — Fairfax, Virginia
Additional sites are listed in Denmark, Finland, France, Spain, Switzerland, and the United Kingdom. UCI Health separately identifies its TEADCO study as open to accrual. Nevertheless, an overall recruiting designation does not establish that every tumor-specific cohort is accepting patients at each location.
Who might qualify?
The study includes adults with advanced, unresectable or metastatic mesothelioma who meet specified medical criteria. Eligibility can depend on previous treatment, overall health, measurable disease, available tumor tissue, and whether the patient can safely receive the study combination. Some stages restrict enrollment after prior immune-checkpoint inhibitor treatment.
Patients and families should confirm current mesothelioma-cohort recruitment, detailed eligibility requirements, and potential travel obligations with the study team and treating oncologist before making plans.
Does the combination improve mesothelioma outcomes?
That has not been established. The TEADCO combination has not demonstrated improved survival, symptom control, or quality of life in mesothelioma patients. Earlier research involving ODM-212 alone is distinct from this combination trial and cannot establish the combination's benefit.
Clinical-trial participation involves potential risks and uncertain benefits. Patients should not delay or stop recommended treatment without discussing the decision with their oncology team.
Why the expanded study network matters
Mesothelioma is an uncommon cancer, and access to specialized clinical trials can depend on geography and enrollment criteria. More listed research centers may offer additional opportunities to inquire about a study, even though individual participation is not guaranteed.
The news is the expansion of a research network—not the approval or demonstrated effectiveness of a new treatment.
Related H&S resources: Mesothelioma Treatment Options and Finding a Mesothelioma Specialist.
Original sources
- ClinicalTrials.gov — TEADCO, NCT07563738
- UCI Health — TEADCO study listing
- University of California — study locations and eligibility
- Registry-derived study listing — location updates
- Orion Pharma — original TEADCO announcement
Medical information notice: Humpleby & Strauss, P.C. is a law firm and does not provide medical treatment or individualized medical advice. ODM-212 remains investigational. Trial enrollment, eligibility, risks, and treatment decisions must be discussed with qualified physicians and study investigators. Editorial standards.